RWReza Wakili

Reza Wakili

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Reza Wakili has a total of 450 co-authors. Here are the top co-authors by number of shared publications:

  • Tienush Rassaf

    Department of Cardiology and Vascular Medicine, West‐German Heart and Vascular Center Essen, University of Essen Medical School University Duisburg‐Essen Essen Germany

    11 shared publications
  • Dobromir Dobrev

    Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany

    8 shared publications
  • Johannes Siebermair

    Department of Cardiology and Vascular Medicine, West‐German Heart and Vascular Center Essen, University of Essen Medical School University Duisburg‐Essen Essen Germany

    6 shared publications
  • Tienush Rassaf

    Department of Cardiology and Vascular Medicine, West-German Heart and Vascular Center Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany

    6 shared publications
  • J. Siebermair

    Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Duisburg-Essen, Essen, Germany

    5 shared publications
  • Nadine Vonderlin

    Department of Cardiology and Vascular Medicine, West‐German Heart and Vascular Center Essen, University of Essen Medical School University Duisburg‐Essen Essen Germany

    5 shared publications

Latest Publications

  • Open Access

    Pacemaker-implantation and atrioventricular-node ablation vs pulmonary vein isolation for elderly patients with persistent atrial fibrillation: the ABLATE vs PACE trial

    by Andreas A Boehmer, Lars Eckardt, Moritz Rothe, Bernhard M Kaess, Florian Doldi, Fatih Guener, Harilaos Bogossian, Konstantinos Iliodromitis, Dirk Bastian, Veronica Buia, et al.

    Background and Aims: Population aging is increasing the prevalence of atrial fibrillation (AF). In elderly patients with persistent AF, pulmonary vein isolation (PVI) has limited success, but is widely used. Pacemaker-implantation with atrioventricular-node ablation (PM+AVNA) provides effective symptom control, but the relative effects of PM+AVNA vs PVI on hospitalizations and other outcomes in the elderly remain unknown. Methods: This investigator-initiated, multicenter, open-label trial randomized patients aged ≥75 years with symptomatic persistent AF and normal left ventricular ejection fraction to PM+AVNA or PVI treatment strategies. The primary endpoint was a composite of hospitalization for atrial arrhythmia or heart failure, outpatient electrical cardioversion or upgrade to cardiac resynchronization therapy for left ventricular dysfunction. Secondary endpoints included all-cause death, stroke, treatment-related complications and quality of life. Results: Twelve centers in Germany and Austria randomized 196 patients (median age 81 years). At 12 months, a first primary endpoint event occurred in 24 of 98 patients (24%) assigned to PM+AVNA and 45 of 98 patients (46%) assigned to PVI (hazard ratio 0.45, 95% confidence interval 0.27 to 0.74; P = .002). A total of 29 and 84 primary endpoint events occurred respectively, consisting principally of arrhythmia-related hospitalizations and cardioversions in the PVI group (54 and 19 respectively, vs 3 and 1 in the PM+AVNA group) and of heart failure-related hospitalizations in the PM+AVNA group (23, vs 11 in PVI group). Mortality, stroke, treatment-related complications, and quality-of-life changes did not show between-group differences. Conclusions: In elderly patients with persistent AF, PM+AVNA was associated with fewer primary endpoint events than PVI over a 12-month follow-up period.

  • Open Access

    PulseSelect vs FARAPULSE pulsed field ablation: comparative analysis of myocardial, neural-injury and hemolysis biomarkers and short-term outcomes

    by Christian Gold, Anastasia Falagkari, Florian Post, Victoria Johnson, Esther Roth, Sinan Justin Kühn, Dominik Linz, Dobromir Dobrev, Julia W. Erath, Laura Rottner, et al.

    Background Randomized trials have demonstrated safety and efficacy of pulsed field ablation (PFA) for atrial fibrillation (AF) using the FARAPULSE™ system (PFA-F). We evaluated implementation of the PulseSelect™ system (PFA-P) in a PFA-F experienced center.MethodsThis single-center study included 150 consecutive patients undergoing first pulmonary vein isolation (PVI) with PFA-P (n=75) or PFA-F (n=75). Procedural characteristics, acute efficacy, safety endpoints, AF recurrence rate, myocardial, neural and hemolysis biomarkers (high-sensitive troponin T, creatine kinase (CK), creatine kinase MB, bilirubin, haptoglobin, lactate dehydrogenase and S100) post ablation were analyzed and compared.ResultsBaseline characteristics were comparable, except for a higher proportion of males in the PFA-F group. Acute PVI was comparable between groups (98% vs. 100%). Skin-to-skin time and radiation dose were similar, while fluoroscopy (14.3 vs. 11.9 min, p=0.009) and LA-dwell time (18 vs. 14min, p<0.001) were higher in PFA-P. No major complication occured, while minor complication rates were comparable. Cardiac biomarker release was significantly higher in PFA-P (ΔCK: 203 vs. 127 U/l, p=0.005; Δtroponin: 1212 vs. 1014 pg/ml, p=0.035 (day 1)), whereas neural injury markers were similar. Hemolysis markers indicated greater changes with PFA-F (Δbilirubin: 0.3 vs. 0.2 mg/dL, p=0.004; Δhaptoglobin: −46.5 vs. −27.5 mg/dL, p=0.001 (day1)). Procedural parameters improved with increasing PFA-P experience.ConclusionImplementation of PFA-P is feasible with an evident learning curve in a PFA-F experienced center. Higher post-procedural cardiac biomarker levels may suggest a greater extent of local myocardial tissue damage after PFA-P. The impact of biomarkers on long-term outcome requires further studies

  • Top Cited Papers

    Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial

    by David Schaack, Kyoung-Ryul Julian Chun, Kars Neven, Andreas Metzner, Christian Heeger, Reza Wakili, Arian Sultan, Andrea Urbani, Nico Reinsch, Andreas Rillig, et al.

    Background and Aims: Vascular access site complications are the most common procedure-related adverse event of atrial fibrillation catheter ablation. Whether ultrasound-guided femoral venous puncture reduces these vascular access complications remains uncertain. Methods: In this investigator-initiated, multicentre, open-label, superiority trial, patients undergoing atrial fibrillation or left atrial tachycardia catheter ablation were randomized to an ultrasound-guided venous puncture strategy (intervention group) or to a conventional venous puncture group guided by palpation (control group). The composite primary outcome was the occurrence of venous access site complications until 30 days after the procedure, defined as arteriovenous fistula, false aneurysm, or access site bleeding requiring intervention or leading to prolonged hospitalization. Secondary endpoints included procedure duration, puncture duration, procedure-related stroke/transient ischaemic attack within 30 days, number of unintended arterial punctures, and number of failed venous access attempts, as well as hospital stay duration. Results: In six centres, 986 patients were randomized. A total of 496 patients were assigned to the ultrasound-guided puncture group, and 490 patients to the conventional puncture group. The trial was stopped for efficacy, following the first interim analysis after enrolment of half of the planned patients. The composite primary outcome occurred in 3 patients (0.6%) in the intervention group and 16 patients (3.3%) in the control group (risk ratio 0.19; 95% confidence interval 0.05–0.63; P = .002). Additionally, ultrasound-guided venous puncture significantly reduced the rate of an unintended arterial puncture (2% vs 16%, P < .0001) and the rate of unsuccessful venous access attempts requiring crossover to the other group (0.2% vs 8.2%, P < .0001). Conclusions: Ultrasound-guided venous access for atrial fibrillation ablation procedures significantly reduced vascular access site complications. ULYSSES ClinicalTrials.gov number: NCT06403527.


  • Open Access

    Sex-Specific Response Rate to Cardiac Resynchronization Therapy – Insights From a Large Multicenter Cohort of CRT-D Recipients

    by Florian Post, Jana Kupusovic, Sarah Keck, Victoria Johnson, Anastasia Falagkari, Christian Gold, Carsten Walter Israel, Gabor Zoltan Duray, Nikolett Vigh, David Manuel Leistner, et al.

    Background: Cardiac resynchronization therapy (CRT) has become a cornerstone in heart failure (HF) therapy. Evidence from randomized controlled trials on the effects of sex on CRT response is scarce. Methods: Perioperative and outcome data were retrospectively collected from 03/2005 to 11/2024 after CRT-D implantation in three tertiary European centers. The primary endpoint was all-cause mortality. Secondary endpoint was response to CRT as measured in improvement of left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), NYHA class, and QRS shortening from implantation to a six month follow up. Findings: The patient cohort comprises 802 consecutive patients (168 female, 634 male). During the median follow-up of 27.6 months [IQR 13-53] female sex was associated with significantly lower mortality (adjusted HR 0.63 [95% CI, 0.4-0.9], p<0.01). Female sex was also associated with a significantly greater echocardiographic CRT response, demonstrated by both a larger increase in LVEF (median ∆LVEF +8.5% [IQR 3–15] vs. +5% [IQR 0–10] in males; p<0.001) and a greater reduction in LVEDD (median ∆LVEDD −2 mm [IQR −7 to 1] vs. −1 mm [IQR −6 to 2]; p<0.05). Regarding other parameters (change in NYHA class, QRS shortening), we found no significant differences. Interpretation: This multicentric cohort study suggests that female sex is an independent predictor for lower all-cause mortality in CRT-D recipients. Moreover, female patients exhibited more pronounced improvements in echocardiographic parameters during follow-up. Based on these data female patients seem to be optimal CRT candidates.

  • Open Access

    Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference

    by Emma Svennberg, Jose Luis Merino, Jason Andrade, Matteo Anselmino, Elena Arbelo, Eric Boersma, Giuseppe Boriani, Günter Breithardt, Mina Chung, Janice Chyou, et al.

    Atrial fibrillation (AF) is a growing unmet medical need. To reduce its impact on patients’ lives, improvements in stroke prevention therapy, treatment of concomitant conditions, and rhythm control therapy are actively developed: Innovations in anti-thrombotic agents, new anti-arrhythmic drugs (AADs), and novel interventional rhythm control therapies emerge alongside AF-reducing effects of general cardiometabolic therapies. Simple risk scores are slowly replaced by personalized AF risk estimation using quantifiable features. These developments were discussed by over 80 experts from academia and industry during the 10th Atrial Fibrillation NETwork /European Heart Rhythm Association consensus conference from 5 to 7 May 2025. The emerging consensus, described here, is multi-domain therapy combining stroke prevention, rhythm control, and therapy of concomitant cardiovascular conditions. This combines anti-coagulants, AADs, and AF ablation with old and new cardiometabolic drugs that can reduce AF risk, AF burden, and AF-related complications at scale. The paper furthermore describes quantitative traits that may enable a shift towards risk-driven therapy based on AF phenotypes. These can enable adjusted therapy strategies that are safe, accessible, and patient-centred. Applying modern data science and artificial intelligence methods to quantitative phenotypic and genetic features can further improve risk estimation and personalized therapy selection. At the same time, translational and clinical research into reversing the drivers of AF and into improved stroke prevention through new drugs and through combination therapies is needed. Together, these efforts offer pathways towards personalized, patient-centred, multi-modal, and accessible AF management that integrates rhythm control, stroke prevention, and therapy of concomitant conditions to bridge today’s practical needs with tomorrow’s therapeutic innovation.


  • Open Access

    Short-term benefit of early rhythm control for atrial fibrillation: the EAST-AFNET 4 trial

    by Julius Obergassel, Anna Suling, Katrin Borof, Alan John Camm, Harry J G M Crijns, Lars Eckardt, Larissa Fabritz, Andreas Goette, Märit Jensen, Marc Daniel Lemoine, et al.


  • Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support

    by Lara S. Schlender, Marco Ochs, Reza Wakili, Robert Stöhr, Fabian Emrich, Thomas Walther, Jan Gummert, Michiel Morshuis, David M. Leistner, Maria Papathanasiou


  • Lateral Atrial Expression Patterns Provide Insights into Local Transcription Disequilibrium Contributing to Disease Susceptibility

    by Aaron Isaacs, Stef Zeemering, Joris Winters, Montserrat Batlle, Elham Bidar, Bas Boukens, Barbara Casadei, Winnie Chua, Harry J.G.M. Crijns, Larissa Fabritz, et al.

    BACKGROUND: Transcriptional dysregulation, possibly affected by genetic variation, contributes to disease etiology. Due to dissimilarities in development, function, and remodeling during disease progression, transcriptional differences between the left atrium (LA) and right atrium (RA) may provide insight into diseases such as atrial fibrillation. METHODS: Lateral differences in atrial transcription were evaluated in CATCH ME (Characterizing Atrial fibrillation by Translating its Causes into Health Modifiers in the Elderly) using a 2-stage discovery and replication design. The design took advantage of the availability of 32 paired samples, for which both LA and RA tissue were obtained, as a discovery cohort, and 98 LA and 69 RA unpaired samples utilized as a replication cohort. RESULTS: A total of 714 transcripts were identified and replicated as differentially expressed (DE) between LA and RA, as well as 98 exons in 55 genes. Approximately 50% of DE transcripts were colocated with another frequently correlated DE transcript ( P FDR ≤0.05 for 579 regions). These “transcription disequilibrium” blocks contained examples including side-specific differential exon usage, such as the PITX2 locus, where ENPEP showed evidence of differential exon usage. Analysis of this region in conjunction with BMP10 identified rs9790621 as associated with ENPEP transcription in LA, while rs7687878 was associated with BMP10 expression in RA. In RA, BMP10 and ENPEP were strongly correlated in noncarriers, which was attenuated in risk-allele carriers, where BMP10 and PITX2 expression were strongly correlated. CONCLUSIONS: These results significantly expand knowledge of the intricate, tissue-specific transcriptional landscape in human atria, including DE transcripts and side-specific isoform expression. Furthermore, they suggest the existence of blocks of transcription disequilibrium influenced by genetics.


  • Open Access

    Delayed 68Ga-FAPI-46 PET/MR imaging confirms ongoing fibroblast activation in patients after acute myocardial infarction

    by Jana Kupusovic, Lukas Kessler, Sandra Kazek, Michal Kamil Chodyla, Lale Umutlu, Fadi Zarrad, Michael Nader, Wolfgang P. Fendler, Zohreh Varasteh, Ken Hermann, et al.